Merck, Inc.
🇵🇭Philippines
Neutrophilic Asthma Study With Navarixin (MK-7123, SCH 527123) (MK-7123-017)(COMPLETED)
Phase 2
Completed
- Conditions
- Neutrophilic Asthma
- Interventions
- First Posted Date
- 2008-03-10
- Last Posted Date
- 2019-01-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 37
- Registration Number
- NCT00632502
Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146)
Phase 2
Terminated
- Conditions
- Carcinoma, Large CellAdenocarcinomaCarcinoma, Non-Small-Cell LungCarcinoma, Squamous Cell
- Interventions
- First Posted Date
- 2008-03-10
- Last Posted Date
- 2017-06-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 53
- Registration Number
- NCT00632203
A Study to Test the Effectiveness and Safety of MK0893 in Combination With Other Drugs Used to Treat Type 2 Diabetes (0893-015)
Phase 2
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: MK-0893Drug: SitagliptinDrug: MetforminDrug: Placebo for MetforminDrug: Placebo for MK-0893Drug: Placebo for Sitagliptin
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2017-01-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 146
- Registration Number
- NCT00631488
Safety and Efficacy Study of AzaSite® in Subjects With Blepharitis
- First Posted Date
- 2008-03-06
- Last Posted Date
- 2011-09-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 25
- Registration Number
- NCT00629941
- Locations
- 🇺🇸
Central Maine Eye Care, Lewiston, Maine, United States
🇺🇸Ophthalmic Research Associates, Andover, Massachusetts, United States
Safety and Efficacy Pilot Study of AzaSite® (Azithromycin) in Subjects With Blepharitis
- First Posted Date
- 2008-03-06
- Last Posted Date
- 2011-09-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 60
- Registration Number
- NCT00629980
- Locations
- 🇺🇸
Sall Research Medical Center, Artesia, California, United States
🇺🇸Tauber Eye Center, Kansas City, Missouri, United States
🇺🇸North Valley Eye Medical Group, Mission Hills, California, United States
Safety and Efficacy Pilot Study of AzaSite (Azithromycin) in Subjects With Blepharitis
- First Posted Date
- 2008-03-06
- Last Posted Date
- 2011-09-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 20
- Registration Number
- NCT00629590
- Locations
- 🇺🇸
South Shore Eye Care, Wantagh, New York, United States
Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis (CF) Lung Disease
Phase 3
Completed
- Conditions
- Cystic Fibrosis
- Interventions
- First Posted Date
- 2008-02-28
- Last Posted Date
- 2015-11-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 466
- Registration Number
- NCT00625612
- Locations
- 🇺🇸
Cystic Fibrosis Institute, Glenview, Illinois, United States
🇺🇸Maine Medical Center, Portland, Maine, United States
🇺🇸Children's Healthcare of Atlanta at Scottish Rite, Atlanta, Georgia, United States
Induced Sputum Study (0000-065)
Phase 1
Completed
- Conditions
- Asthma
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2015-05-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 13
- Registration Number
- NCT00623714
Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)
Phase 3
Completed
- Conditions
- Chemotherapy-Induced Nausea and Vomiting (CINV)
- Interventions
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 2322
- Registration Number
- NCT00619359
Efficacy and Safety of Odanacatib (MK-0822) in Participants With Involutional Osteoporosis (MK-0822-022)
Phase 2
Completed
- Conditions
- Osteoporosis Postmenopausal
- Interventions
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 287
- Registration Number
- NCT00620113
© Copyright 2025. All Rights Reserved by MedPath